Nevro Stock Forecast, Price & News

Nevro (NYSE:NVRO) Frequently Asked Questions

Is Nevro a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Nevro stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View analyst ratings for Nevro or view top-rated stocks.

How has Nevro's stock price been impacted by Coronavirus?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has decreased by 22.2% and is now trading at $85.45.
View which stocks have been most impacted by COVID-19.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Nevro.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) released its quarterly earnings results on Sunday, November, 7th. The medical equipment provider reported ($0.86) EPS for the quarter, beating the Zacks' consensus estimate of ($0.87) by $0.01. The medical equipment provider earned $93.21 million during the quarter, compared to analyst estimates of $91.59 million. Nevro had a negative net margin of 27.51% and a negative trailing twelve-month return on equity of 24.68%. The company's quarterly revenue was down 14.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.29) earnings per share.
View Nevro's earnings history.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its fourth quarter 2021 earnings guidance on Monday, November, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $94 million-$98 million, compared to the consensus revenue estimate of $111.49 million.

What price target have analysts set for NVRO?

14 brokers have issued 1 year price objectives for Nevro's shares. Their forecasts range from $104.00 to $205.00. On average, they expect Nevro's stock price to reach $130.83 in the next year. This suggests a possible upside of 53.1% from the stock's current price.
View analysts' price targets for Nevro or view top-rated stocks among Wall Street analysts.

Who are Nevro's key executives?

Nevro's management team includes the following people:

• D. Keith Grossman, Chairman, President & Chief Executive Officer
• Patrick Schmitz, Vice President-Operations
• Roderick H. MacLeod, Chief Financial Officer
• David Caraway, Chief Medical Officer
• Christopher Christoforou, Vice President-Technical Operations

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

Who are some of Nevro's key competitors?

Some companies that are related to Nevro include Hill-Rom (HRC), NovoCure (NVCR), Penumbra (PEN), Tandem Diabetes Care (TNDM), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Beauty Health (SKIN), Merit Medical Systems (MMSI), AtriCure (ATRC), iRhythm Technologies (IRTC) and Haemonetics (HAE).
View all of NVRO's competitors.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (11.50%), Invesco Ltd. (4.04%), Capital Research Global Investors (3.92%), Franklin Resources Inc. (2.62%), Wellington Management Group LLP (1.91%) and Geode Capital Management LLC (1.61%). Company insiders that own Nevro stock include Andrew H Galligan, D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Wolverine Asset Management LLC, Voya Investment Management LLC, BNP Paribas Asset Management Holding S.A., Goldman Sachs Group Inc., Franklin Resources Inc., Natixis, Victory Capital Management Inc., and Deutsche Bank AG. Company insiders that have sold Nevro company stock in the last year include Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro or view top insider-selling stocks.

Which institutional investors are buying Nevro stock?

NVRO stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Capital Research Global Investors, Balyasny Asset Management LLC, Wellington Management Group LLP, MARSHALL WACE ASIA Ltd, Massachusetts Financial Services Co. MA, ArrowMark Colorado Holdings LLC, and BlackRock Inc.. Company insiders that have bought Nevro stock in the last two years include D Keith Grossman, Elizabeth H Weatherman, and Kashif Rashid.
View insider buying and selling activity for Nevro or or view top insider-buying stocks.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $85.45.

How much money does Nevro make?

Nevro has a market capitalization of $2.98 billion and generates $362.05 million in revenue each year. The medical equipment provider earns $-83.07 million in net income (profit) each year or ($3.12) on an earnings per share basis.

How many employees does Nevro have?

Nevro employs 843 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

Where are Nevro's headquarters?

Nevro is headquartered at 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at [email protected].